Immunoglobulin E is one of the five classes of immunoglobulins (IgM, IgG, IgD, IgA, IgE). It was the last of the immunoglobulin family to be discovered, and since then has spurred vast amounts of research aimed at characterizing its biochemistry and role in disease processes. Not only does IgE have a unique chemical structure, but it also has an array of physiological functions such as Type I hypersensitivity reactions, parasitic infections, autoimmune processes, and even venom protection. There have also been advancements in technology used to evaluate patient IgE levels, in addition to new pharmacological therapies that may inhibit its function altogether. The following article aims to provide an overview detailing the biochemical structure and function of Immunoglobulin E, as well as some examples of its clinical implications.
All immunoglobulin molecules have a common structural framework characterized by two identical small polypeptide chains (light chains) and two identical large polypeptide chains (heavy chains). The Fc region of the antibody is comprised solely of the two heavy chains and is responsible for binding to cellular receptors. The Fab region of the antibody is where antigen recognition and binding occur and is made up of two heavy chains continuous with the Fc region, as well as two light chains. These chains also have variable and constant regions. At the antigen binding sites, both polypeptide chains contain variable regions whose amino acid sequences can be altered for affinity maturation to occur for a given antigen. The variable heavy and light chains are organized into layers of antiparallel B-pleated sheets, allowing for the antigen to bind between these three-dimensional immunoglobulin folds. The rest of the polypeptide regions are known as constant regions, and they are held together by strong dipeptide bonds to stabilize the two chains.
Some antibodies like IgM can have five duplicates of the structure above to form a pentamer capable of binding up to ten antigens. However, IgE is a monomer composed of two epsilon-heavy chains and two light chains thus capable of binding a total of two antigens, which occurs through by the variable regions of the light and heavy chains that create unique antigen-specific binding sites. The C-terminal regions of the heavy chains are composed of four C-epsilon dimers, C-epsilon 1-4. The chemical structure of these dimers is essential for binding IgE specific cellular receptors Fc-epsilon R1 and CD23 which will be discussed in more detail later. Some immunoglobulins, such as IgG, contain a “hinge” region near the center of the molecule. IgE is unique in that it lacks this hinge region and gets replaced by the C-epsilon2 domain. There is a theory that the lack of this hinge region allows the IgE molecule to adopt a more flexible conformation while interacting with its receptors. Furthermore, the IgE molecule is more heavily glycosylated than other antibodies, containing 7 N-linked glycosylations on each heavy chain, one that is necessary for binding to a high-affinity cellular receptor, Fc-epsilon-R1.
The biochemical considerations mentioned not only determine the structure of IgE but also drive the function of allowing IgE to bind to given antigens, as well as to IgE-specific cellular receptors. For Immunoglobulin E to accomplish its function, the Fc portion of the antibody must bind to a given cellular receptor located on a particular type of cell such as a mast cell, eosinophil, etc. Although many cellular receptors have been identified and studied, the main ones are Fc-epsilon-RI and Fc-epsilon-RII, or CD23. Fc-epsilon-RI, or the high-affinity receptor, is mainly located on mast cells, basophils, dendritic cells, macrophages, and eosinophils. It is thus responsible for immediate hypersensitivity reactions, parasitic immunity, enhanced cytokine production, and antigen presentation. The other receptor, CD23, or the low-affinity receptor, is primarily expressed on B-cells, T-cells, antigen-presenting cells (APCs) and is responsible for IgE production homeostasis, facilitated antigen presentation (FAP), as well as transportation of IgE across airway and gut epithelia.
The role of Immunoglobulin E is central in allergy sensitization and atopic disorders such as allergic rhinitis, asthma, and atopic dermatitis. These disorders manifest due to Type I hypersensitivity reactions involving IgE and other immune cells to ultimately produce the clinical symptoms seen in those disorders. It all starts with an initial exposure to an antigen or allergen which is taken up and processed by a dendritic cell or macrophage which presents the antigen to a T cell. In the presence of cytokine mediators IL-4 and IL-13, these T cells are induced to differentiate into TH2 helper T cells capable of presenting the antigen to B-cells. The B-cells then undergo class-switching recombination events to ultimately produce Immunoglobulin E antibodies capable of binding to the presented antigen at the “antigen binding site” of the Fab portion of the antibody. Once this initial sensitization to antigen has occurred, more immunological events can take place to ensure a more robust IgE response. The CD23 receptor on intestinal or airway epithelial cells can transport antigen-IgE complexes across the epithelium to bind Fc-epsilon-RI receptors on mast cells, macrophages and other immune cells to promote inflammation, cytokine production, and more local IgE production. Furthermore, via interaction with the CD23 receptor on B-cells and myeloid cells, a process is known as facilitated antigen presentation (FAP) can occur. FAP involves antigen-IgE complexes binding to CD23 receptors on B-cells, which then present the peptides to T-cells to facilitate further IgE antibody production. This approach contrasts with the classical antigen presentation pathway described above, for instead of T-cells being the primary antigen presenters to the B-cell, it is now antigen-IgE complexes formed in the periphery which may or may not be related to the initial antigen. This has clinical importance because, via facilitated antigen presentation, the B-cells will ultimately present a diverse array of peptides to T-cells to clear it for further immunoglobulin production. In conclusion, this is a mechanism for epitope spreading, where an antibody response for one antigen can cause the production of antibodies to different antigens. This could be a reason why individuals can develop allergies to multiple antigens resulting in a phenomenon known as ‘atopic march.’ For example, a child could have atopic dermatitis and later in life develop asthma. In conclusion, facilitated antigen presentation produces a more robust immune response to a given antigenic exposure that could be responsible for sensitization to multiple, unrelated antigens.
Once initial exposure to an antigen has occurred, and an immune response has been activated, antigen-specific IgE will remain bound via Fc-epsilon RI receptor to mast cells and basophils. It has been shown that binding alone of IgE to that receptor cause IgE-dependent upregulation of mast cell Fc-epsilon RI receptor expression, which allows these cells to bind more IgE antibodies. Furthermore, it is important to note that IgE has a short half-life in plasma, usually less than a day. However, IgE bound to a high-affinity receptor (Fc-epsilon RI) can remain attached to mast cells in tissues for weeks to months. Later, upon re-exposure to a given antigen, crosslinking of adjacent Fc-epsilon RI-bound IgE antibodies occurs and binds the antigen which causes subsequent aggregation of Fc-epsilon RI receptors. Once this occurs and there is sufficient aggregation of these receptors with bound antigen, it causes mast cells and basophils to release preformed chemical mediators stored in cytoplasmic granules such as histamine, serotonin, tryptase, prostaglandins, leukotrienes and eosinophil/neutrophil chemotactic factors.
It is essential to note that not everyone exposed to environmental antigens will generate a robust immune reaction described above. Certain people known as ‘atopics’ have a genetic predisposition for generating type one hypersensitivity responses to antigens in the environment. Clinically, the manifestations of this type one hypersensitivity reaction are usually due to the actions of the released chemical mediators such as histamine, leukotrienes, and other cytokines. Histamine release causes increased vascular permeability, smooth muscle constriction, and increased mucus secretion. Leukotrienes B4, C4, D4, and E4 are also often secreted which are responsible for chemotaxis, inflammation, and anaphylaxis. Furthermore, if in enough quantity, histamine and other mediators can cause systemic vascular effects such as vasodilation and increased vessel permeability causing hypotension and edema. If severe enough and not properly managed, this could lead to anaphylactic shock and death.
The manifestations can occur in many different areas of the body. Involvement of the upper airway can cause many patients to suffer from mild seasonal allergies or allergic rhinitis. Due to repeated inhalation exposure to pollen and other outdoor antigens, type one hypersensitivity occurs, and mast cell degranulation causes epiphora, rhinorrhea, cough, and other symptoms. Additionally, the involvement of the lower airway in patients with atopic asthma experience immune response to aeroallergens resulting in airway smooth muscle constriction, increased mucus production, and inflammation that manifests as obstructive lung disease. The skin can often be involved, and due to vasodilation and dermal edema, urticaria or ‘wheals’ can be evident. Another skin disease that has been a topic of study concerning the roles of IgE and hypersensitivity is atopic dermatitis or eczema. Although eczema is a multifactorial disease involving genetics, barrier dysfunction, and immune dysregulation, there is some evidence suggesting IgE mediated hypersensitivity may also play a role. The inflammatory infiltrates of AE lesions is composed mainly of CD4+ helper T cells, with a predominance of TH2 cells which are responsible for initiating IgE class switching by B cells. Certain aeroallergens were found to penetrate compromised skin in eczema patients and interact with Langerhans cells. Furthermore, these same cells were discovered to have IgE binding structures on their surface. There has also been a correlation revealing that up to 80 to 85 percent of patients with atopic dermatitis have elevated IgE levels. One study even conducted atopy patch tests on eczema patients and correlated their allergen-specific serum IgE. It showed that a majority of patients (40%, N=151) with positive atopy patch test for D. pteronyssinus (house dust allergen) also had elevated serum IgE specific for that antigen. This study also demonstrated that there were patients (9%) with positive atopy patch test and no elevation in serum IgE, in addition to other patients that had a negative patch test altogether. Thus, given the known multifactorial nature of atopic dermatitis, it is likely that some correlation may exist between IgE-mediated hypersensitivity and eczema. However, the exact nature of this relationship requires further investigation.
Immunoglobulin E has also been implicated in the defense against parasitic organisms such as helminths. Helminthic infections are usually the result of soil transmission and infect up to one-third of people worldwide. When the immune system encounters this type of parasite, B-cells class switch to IgE antibodies, which then ‘coat’ the parasite via binding of many antibodies. Following this, effector cells such as eosinophils and mast cells recognize Immunoglobulin E bound to the helminth and can then bind the Fc portion of the antibody via the Fc-epsilon RI receptor. Once bound, subsequent reactions occur such as further cytokine release and the production of histamine by mast cells, as well as major basic protein and eosinophil peroxidase production by eosinophils. These substances are toxic to the helminth and can thus result in parasitic killing and ultimate clearance of the invader.
As depicted in this article, Immunoglobulin E has a specific biochemical structure and function that guides its unique role in disease processes such as Type I hypersensitivity reactions, helminthic infections, and more. The research put forth in the past 50 years regarding IgE has established a better idea of its role in disease. Not only has this aided in a more in-depth clinical understanding of IgE-related health disorders, but has even spurred novel treatment modalities. A humanized monoclonal antibody named omalizumab has been engineered which targets the IgE antibody thus rendering ineffective in producing associated symptoms. This drug has shown to provide benefit and relief in patients with moderate to severe asthma, as well as patients with intermittent and persistent allergic rhinitis. Despite this progress, much more remains to be learned about the exact function of this immunoglobulin in those diseases in which some correlation has already been established, as well as novel clinical relationships yet to be discovered.
|||Schroeder HW Jr,Cavacini L, Structure and function of immunoglobulins. The Journal of allergy and clinical immunology. 2010 Feb; [PubMed PMID: 20176268]|
|||Oettgen HC, Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. The Journal of allergy and clinical immunology. 2016 Jun; [PubMed PMID: 27263999]|
|||Galli SJ,Tsai M, IgE and mast cells in allergic disease. Nature medicine. 2012 May 4; [PubMed PMID: 22561833]|
|||Amarasekera M, Immunoglobulin E in health and disease. Asia Pacific allergy. 2011 Apr; [PubMed PMID: 22053291]|
|||Justiz Vaillant AA,Zito PM, Immediate Hypersensitivity Reactions 2019 Jan; [PubMed PMID: 30020687]|
|||Thomsen SF, Atopic dermatitis: natural history, diagnosis, and treatment. ISRN allergy. 2014; [PubMed PMID: 25006501]|
|||Darsow U,Ring J, Immunoglobulin e-mediated allergy plays a role in atopic eczema as shown in the atopy patch test. The World Allergy Organization journal. 2008 Mar; [PubMed PMID: 23283386]|
|||Liu FT,Goodarzi H,Chen HY, IgE, mast cells, and eosinophils in atopic dermatitis. Clinical reviews in allergy [PubMed PMID: 21249468]|
|||McSorley HJ,Maizels RM, Helminth infections and host immune regulation. Clinical microbiology reviews. 2012 Oct; [PubMed PMID: 23034321]|
|||Anthony RM,Rutitzky LI,Urban JF Jr,Stadecker MJ,Gause WC, Protective immune mechanisms in helminth infection. Nature reviews. Immunology. 2007 Dec; [PubMed PMID: 18007680]|
|||Kelly BT,Grayson MH, Immunoglobulin E, what is it good for? Annals of allergy, asthma [PubMed PMID: 26945494]|